Novel Targets for Drug Discovery in Oncology - Biowebspin | Biowebspin
Logo Biowebspin


The worldwide platform to find industrial partners and funding

External open innovation partner programNovel Targets for Drug Discovery in Oncology

Have you identified novel targets or mechanisms of action that would enable the development of new cancer therapeutics? Are you interested in partnering with a top 5 pharma company to translate your new science into a new medicine?
What we are looking for

We are looking for novel and actionable targets, whose inhibition will block tumor growth in molecularly well-defined patient populations.

We are specifically interested in targets for precision medicine, i.e. targets, that are (i) mutated or (ii) abnormally expressed in specific patient populations, and whose inhibition will halt tumor growth in precisely this patient population. (iii) Targets that become essential for tumor cell survival and whose inhibition will be lethal in a particular genetic context (concept of synthetic lethality). We are looking for targets involved in (iv) resistance to therapy or (v) targets which are relevant in a molecular context where immune modulating agents have shown to be inactive.

We are not looking for strict immune modulators.

At discovery stage, new molecular targets must be supported by clear scientific data deriving from in vitro (compulsory), ex vivo, or animal models (a plus).

What we offer and how does it work

All proposals will be assessed by our Research & Development team. Based on the level of interest within the Company research portfolio and strategic fit, we will enter into discussion with selected candidate(s), potentially leading to partnership agreements or collaborations.

Proponents that submit proposals of interest will be contacted to clarify additional details.

What to submit

Submit a proposal in a form which is available online (it takes about 15 minutes). The proposal should be brief, sufficient to provide the main body of the proposal and its innovativeness. The applicant should also provide information about his or her critical knowledge that is applicable for the project, and how the knowledge could be supplemented (i.e., what is additionally required to complete the project). The applicants are strongly encouraged to give us additional information including references or other materials to facilitate the evaluation process.

Must have:
1. Description of the target, its function, its biological pathway, and the genetic context in which it is relevant to one of the following oncology indications
1.a.Breast cancer
1.b.Gastrointestinal / colorectal cancers
1.c.Non-small cell lung carcinoma (NSCLC)
1.d.Prostate cancer
1.e.Multiple myeloma

2. Target validation data (literature and/or own data)

3. Well-supported rationale for why the Solver believes that the proposal offers a new avenue for research

4. Outline of key experiments and assays needed to demonstrate feasibility

Nice to have:
1. Target can be linked to patient-derived data (e.g. human tumor specimens, patient-derived xenograft models)

2. First-in-class target

3. Suitable for more than one indication or targets a substantial portion of the patient population

4. Validation data informing druggability assessment (e.g. crystal structure of the target protein)

5. Tool compound(s) or optimally, a lead series

Sanofi is open to all possibilities, including opportunities for contractual arrangement which might involve a funding research program or a licensing proposition including milestone compensation and exclusive rights for the development of the proposed approach.

Privacy, confidentiality & FAQ

The Company will not share the information beyond its own staff and its Consultants; your initial proposal should contain only non-confidential information.
If your proposal is selected, the Company is open to complete a Confidentiality Disclosure Agreement (CDA).


Biowebspin pays a lot of attention to the privacy, intellectual property, confidentiality and security of its member data.

Biowebspin is a matchmaking platform between academia & industry. Biowebspin is not involved in the IP discussion and is not charging any success or license fees. Your «Open Innovation» opportunities on Biowebspin are only visible by industrials and the Biowebspin team. You can remove your data at any time. Biowebspin strongly recommends that you do not enter any confidential data or if you do so, that your technology transfer office agrees the submission of your pre-proposal on Biowebspin. If you directly submit your pre-proposal on an industrial partner website, you will agree their terms, conditions and privacy policy of our industrial partner website. Biowebspin is not responsible for the content, accuracy, or opinion of its industrial partner website. As a Swiss International company, Biowebspin has high standard security and privacy system. Biowebspin is in accordance with the Federal Data Protection and Information Commissioner. Contact us for more information about the terms and conditions of the matchmaking service of Biowebspin.


Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur, and Consumer Healthcare. For more information, visit

About Biowebspin:

Biowebspin is the #1 academia-industry partnering network in Life Sciences.
For academics, Biowebspin is the platform to find industrial partners and funding for their research projects matching R&D programs of more than 500 leading Life Sciences companies and foundations.

Check if one program will fit your researches for industrial collaboration and funding